All In Biotech

Drug Trial Radar · NCT05115942

Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

248

Actual

Start

Dec 30, 2021

Primary completion

Oct 22, 2024

Study completion Oct 22, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment, multicentre clinical study. The main objective of this study was to confirm the efficacy and safety of hydronidone in the treatment of chronic hepatitis B liver fibrosis.

Conditions

  • Liver Fibrosis

Interventions

  • Hydronidone capsulesDrug

    After randomization, the experimental group were orally received hydronidone capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d,30 min before meals for 52 weeks.

  • The placebo capsulesDrug

    After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Ishak stage score of liver fibrosis by greater than or equal to 1 point after 52 weeks of treatment relative to baseline.Time frame: 52 weeks

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

    Hefei, Anhui, China

  • Beijing Ditan Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing You 'an Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Tsinghua Changgeng Hospital, Beijing

    Beijing, Beijing Municipality, China

  • Chongqing Public Health Medical Treatment Center (Chongqing Infectious Disease Hospital)

    Chongqing, Chongqing Municipality, China

  • Chongqing Three Gorges Central Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fujian, Fujian, China

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, Fujian, China

  • Lanzhou university first hospital

    Lanzhou, Gansu, China

  • Shenzhen Third People's Hospital

    Shenzhen, Guangdong, China

  • Guizhou Provincial People's Hospital

    Guizhou, Guizhou, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • Hangzhou Xixi Hospital (Hangzhou Sixth People's Hospital)

    Hangzhou, Hangzhou, China

  • The First Hospital of Hebei Medical University

    Hebei, Hebei, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Henan Provincial People's Hospital

    Henan, Henan, China

  • The First Affiliated Hospital of Xinxiang Medical College

    Xinxiang, Henan, China

  • Zhengzhou Sixth People's Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Hunan University of Chinese Medicine

    Changsha, Hunan, China

  • The Second Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of University of South China

    Yueyang, Hunan, China

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of SuZhou University

    Suzhou, Jiangsu, China

  • Taizhou People's Hospital

    Taizhou, Jiangsu, China

  • Wuxi Fifth People's Hospital

    Wuxi, Jiangsu, China

  • Affiliated Hospital of Xuzhou Medical College

    Xuzhou, Jiangsu, China

  • Zhenjiang Third People's Hospita

    Zhenjiang, Jiangsu, China

  • Nanchang Ninth Hospital (Nanchang Central Hospital)

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • First Hospital of Jilin University

    Jilin City, Jilin, China

  • Second Hospital of Jilin University

    Jilin City, Jilin, China

  • Yanbian University Affiliated Hospital

    Yanbian, Jilin, China

  • Shanghai General Hospital,Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Jiao Tong University Affiliated Tongren Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Public Health Clinical Center

    Shanghai, Shanghai Municipality, China

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.